PMID- 32303486
OWN - NLM
STAT- MEDLINE
DCOM- 20210907
LR  - 20210907
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 20
IP  - 9
DP  - 2020 Sep
TI  - Management of Adverse Events From the Combination of Rituximab and Lenalidomide 
      in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma.
PG  - 563-571
LID - S2152-2650(20)30142-7 [pii]
LID - 10.1016/j.clml.2020.03.009 [doi]
AB  - Frontline treatment for patients with indolent non-Hodgkin lymphoma often 
      includes immunochemotherapy. Although the disease of most patients responds to 
      initial treatment, relapse is common. Recent results from the phase 3 Augment 
      trial showed that combining rituximab with the immunomodulatory drug lenalidomide 
      (R(2)) significantly improved efficacy over rituximab monotherapy in patients 
      with recurrent non-Hodgkin lymphoma. As a result of these data, R(2) was approved 
      in the US (Food and Drug Administration) and Japan (Pharmaceuticals and Medical 
      Devices Agency) for previously treated adult patients with follicular and 
      marginal zone lymphoma; and by the European Medicine Agency and the Swiss Agency 
      for Therapeutic Products (Swissmedic) for previously treated adult patients with 
      follicular lymphoma. R(2) has also been studied as initial treatment, where 
      results have been comparable, but not superior, to chemoimmunotherapy. The 
      resulting expanded use of R(2) reinforces the need for a detailed review of its 
      safety profile and management, as presented here. Tolerability of R(2) has been 
      consistent among trials, with most adverse events (AEs) being predictable and 
      manageable. Hematologic AEs, particularly grade 3/4 neutropenia; low-grade 
      cutaneous reactions, such as rash; and gastrointestinal AEs represent the most 
      common AEs associated with R(2). The general R(2) safety profile and optimal 
      strategies for AE management are discussed.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Cheson, Bruce D
AU  - Cheson BD
AD  - Lymphoma Research Foundation, New York, NY. Electronic address: 
      bdcheson@gmail.com.
FAU - Morschhauser, Franck
AU  - Morschhauser F
AD  - University of Lille, CHU Lille, Lille, France.
FAU - Martin, Peter
AU  - Martin P
AD  - Department of Medicine, Weill Medical College of Cornell University, New York, 
      NY.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200320
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 4F4X42SYQ6 (Rituximab)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse 
      effects/pharmacology/therapeutic use
MH  - Drug-Related Side Effects and Adverse Reactions/*therapy
MH  - Female
MH  - Humans
MH  - Lenalidomide/*adverse effects/pharmacology/therapeutic use
MH  - Lymphoma, Follicular/*drug therapy/pathology
MH  - Lymphoma, Non-Hodgkin/*drug therapy/pathology
MH  - Male
MH  - Neoplasm Grading
MH  - Rituximab/*adverse effects/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Anti-CD20
OT  - Augment
OT  - IMiD
OT  - Relevance
OT  - Safety
EDAT- 2020/04/19 06:00
MHDA- 2021/09/08 06:00
CRDT- 2020/04/19 06:00
PHST- 2020/02/21 00:00 [received]
PHST- 2020/03/12 00:00 [revised]
PHST- 2020/03/14 00:00 [accepted]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2021/09/08 06:00 [medline]
PHST- 2020/04/19 06:00 [entrez]
AID - S2152-2650(20)30142-7 [pii]
AID - 10.1016/j.clml.2020.03.009 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):563-571. doi: 
      10.1016/j.clml.2020.03.009. Epub 2020 Mar 20.